2006 proposed fee schedule - American Society of Clinical Oncology

number of 11-digit NDCs sold for each NDC assigned to the
billing code, and then divide by the total number of NDCs
sold. The ASP per billing unit for each NDC is weighted
equally regardless of package size.
d. Reporting WAC
241
In response to manufacturer’s questions about reporting
WAC, we posted a Frequently Asked Question on this subject
on our website (http://www.questions.cms.hhs.gov) last year.
In the posting on the website, we state that manufacturers
must report the WAC for a single source drug or biological
if it is less than the ASP for a quarter and in cases where
the ASP during the first quarter of sales is unavailable.
Upon further review, we have determined that the WAC must be
reported each quarter if required for payment to be made
under section 1847A of the Act, in addition to the ASP, if
available.
Section 1927(b)(3)(A)(iii) of the Act specifies the ASP
data manufacturers must report. Section
1927(b)(3)(A)(iii)(II) of the Act specifies that the
manufacturer must report the WAC, if it is required in order
for payment to be made under section 1847A of the Act.
Under section 1847A of the Act, the payment is based on WAC
(as opposed to ASP) in the following cases:
• For a single source drug or biological, when the
WAC-based calculated payment is less than the ASP-based